Form 13-F position report

FORTE BIOSCIENCES

Reported by STATE STREET CORPORATION

FBRX CUSIP 34962G109 Manager CIK 0000093751

Reported 41,664 shares, unchanged from the prior quarter.

Reported value 3.0%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 41,664 Quarter-end amount reported
Reported value $43,331 Fair value at quarter end
Consecutive quarters held 9 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 1201000
2022-03-31 723000
2022-06-30 54000
2022-09-30 45000
2022-12-31 41664
2023-03-31 42081
2023-06-30 43331
2023-09-30 27582
2023-12-31 34235
2024-03-31 29194
2024-06-30 20172
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for FORTE BIOSCIENCES held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -37,564 (-100.0%) 0 $0 2024-11-14
Q2 2024 Reduced 37,564 -4,100 (-9.8%) < 0.01% $20,172 2024-08-14
Q1 2024 Unchanged 41,664 0 (0.0%) < 0.01% $29,194 2024-05-15
Q4 2023 Unchanged 41,664 0 (0.0%) < 0.01% $34,235 2024-02-14
Q3 2023 Unchanged 41,664 0 (0.0%) < 0.01% $27,582 2023-11-14
Q2 2023 Unchanged 41,664 0 (0.0%) < 0.01% $43,331 2023-08-14
Q1 2023 Unchanged 41,664 0 (0.0%) < 0.01% $42,081 2023-05-15
Q4 2022 Unchanged 41,664 0 (0.0%) < 0.01% $41,664 2023-02-14
Q3 2022 Unchanged 41,664 0 (0.0%) < 0.01% $45,000 2022-11-15
Q2 2022 Reduced 41,664 -453,534 (-91.6%) < 0.01% $54,000 2022-08-15
Q1 2022 Reduced 495,198 -66,150 (-11.8%) < 0.01% $723,000 2022-05-16
Q4 2021 Added 561,348 +97,456 (21.0%) < 0.01% $1,201,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

33 managers reported FORTE BIOSCIENCES for Q2 2023.

Managers reporting FORTE BIOSCIENCES in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BML Capital Management LLC Unchanged 1,735,075 0 1.62% $1,804,478 3 qtrs
VANGUARD GROUP INC Added 664,830 +17,282 < 0.01% $691,423 13 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 204,800 -8,700 < 0.01% $213,000 6 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 193,333 +143 < 0.01% $201,066 13 qtrs
BlackRock Inc Reduced 182,326 -9,081 < 0.01% $189,619 13 qtrs
Old Well Partners LLC Unchanged 68,600 0 0.06% $71,344 4 qtrs
TWO SIGMA INVESTMENTS LP Reduced 57,864 -500 < 0.01% $60,179 7 qtrs
TWO SIGMA ADVISERS LP Reduced 57,591 -7,700 < 0.01% $59,895 7 qtrs
MILLENNIUM MANAGEMENT LLC Reduced 57,102 -41,615 < 0.01% $59,386 11 qtrs
STATE STREET CORPORATION This report Unchanged 41,664 0 < 0.01% $43,331 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
41,664
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.